LGVN News and Press, Longeveron Inc. From 05/09/22

Longeveron (NASDAQ:LGVN) said Monday CEO Geoff Green will resign effective Jun. 1 to pursue new opportunities. LGVN appointed current chief medical officer K. Chris Min as interim CEO to succeed Green. The board retained an executive search firm to select a permanent CEO. LGVN intends to ente...

-Geoff Green stepping down as CEO, effective June 1, 2022 -K. Chris Min, M.D., Ph.D., current Chief Medical Officer, appointed Interim CEO -Nationwide search is underway for permanent CEO MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("...

MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first qua...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any  of Tom’s potential 100x picks,  subscribe to his mailing list here . A Recession ...

A phase 2a study using Lomecel-B for Alzheimer's Disease is currently enrolling patients; a prior phase 1 study established excellent safety profile with some efficacy. The global Alzheimer's Disease market could reach $25 billion by 2027. Lomecel-B has several shots on goal; besi...

MIAMI, April 14, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today its Chief Science Officer, Co-Founder, ...

Longeveron (NASDAQ:LGVN) signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) for the addition of a Miami VA clinical site to its ongoing phase 2 Alzheimer’s Disease (AD) trial. The phase 2 trial, dubbed CLEAR MIND, cons...

Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent that it interferes with a person’s daily life and ac...

MIAMI, April 13, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today a Cooperative Research and Development ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any  of Tom’s potential 100x picks,  subscribe to his mailing list here . Rising Rates...